Standout Papers

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 ye... 2020 2026 2022 2024901
  1. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial (2020)
    Yanjun Zhang, Gang Zeng et al. The Lancet Infectious Diseases

Immediate Impact

4 from Science/Nature 66 standout
Sub-graph 1 of 21

Citing Papers

From periphery to center stage: 50 years of advancements in innate immunity
2024 Standout
Polymeric Nanoparticles for Drug Delivery
2024 Standout
2 intermediate papers

Works of Weixiao Han being referenced

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
2020 Standout

Author Peers

Author Last Decade Papers Cites
Weixiao Han 821 56 68 286 105 7 952
Minnan Yang 916 42 75 285 207 8 1.1k
Xin Chen 889 40 120 285 153 16 1.1k
Katie E. Flight 628 32 88 193 173 7 892
Sophie L. Higham 676 28 106 192 223 6 971
Omri Bodenheimer 908 27 60 392 71 10 1.0k
Mona Marin 627 42 108 518 84 5 1.1k
Oluwaseye Ayoola Ogun 771 22 76 390 60 17 1.0k
Gregory Barnsley 530 25 98 309 78 5 839
Adina Bar‐Chaim 703 24 47 190 75 18 912
Tal Gonen 820 20 63 234 75 16 971

All Works

Loading papers...

Rankless by CCL
2026